Table 4. Factors associated with CD4:CD8 ratio normalisation (ratio >1) by month 12.

	OR	95% CI	p-value	p-overall**	OR	95% CI	p-value	p-overall
AHOD
TAHOD	0.401	(0.303, 0.531)	<0.001		1.145	(0.789, 1.661)	0.475***
Female	1.274	(0.910, 1.785)	0.158
Age per 10 years	1.134	(1.002, 1.283)	0.047		1.159	(1.006, 1.335)	0.041
MSM*
Heterosexual	0.606	(0.455, 0.806)	0.001	0.005
IDU	0.547	(0.217, 1.378)	0.201
Other/missing	0.744	(0.444, 1.245)	0.260
BL CD4 per 20 mm3	1.088	(1.075, 1.102)	<0.001		1.044	(1.015, 1.073)	0.002
BL CD8 per 20 mm3	0.990	(0.985, 0.996)	0.001		0.988	(0.976, 0.999)	0.038
BL ratio (continuous)	102.783	(58.553, 180.424)	<0.001		20.716	(7.094, 60.499)	<0.001
Never HBV
HBV positive ever	0.594	(0.298, 1.185)	0.139	0.325
Missing	0.935	(0.681, 1.284)	0.678
Never HCV
HCV positive ever	1.294	(0.773, 2.166)	0.328	0.532
Missing	0.934	(0.672, 1.298)	0.685
Prior AIDS	0.311	(0.215, 0.449)	0.000		0.629	(0.420, 0.942)	0.024
ART combination**
NNRTI (no PI, no InSTI)
PI (no NNRTI, no InSTI)	1.555	(1.168, 2.071)	0.002	0.000	1.050	(0.756, 1.458)	0.771	0.016
Other (NRTI only or NNRTI+PI, etc)	1.524	(0.745, 3.116)	0.249		0.742	(0.307, 1.795)	0.508
INSTI	6.095	(3.260, 11.396)	<0.001		3.151	(1.523, 6.518)	0.002

^*MSM: men who have sex with men; IDU: injection drug users, BL: baseline.

^**P-values reported for test of homogeneity in nominal covariates and test for trend in ordinal covariates.

^***NRTI: nucleos(t)ide reverse transcriptase inhibitor, NNRTI: non-nucleoside reverse transcriptase inhibitor, PI: protease inhibitor, InSTI: Integrase inhibitor.

^****In multivariate analysis COHORT is adjusted for the independent risk factors.